In 1996, Allison and colleagues showed that antibodies blocking CTLA-4 could induce tumor rejection in mice [161], suggesting the potential to treat cancer by modulating the immune system rather than directly targeting cancer cells. This evidence concerns the gene CTLA4 and cancer.